No article text was recorded for this version.
limitations of conventional cancer therapies
Version 1 of 1103 papers111 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Trifluoperazine and Its Analog Suppressed the Tumorigenicity of Non-Small Cell Lung Cancer Cell; Applicability of Antipsychotic Drugs to Lung Cancer Treatment
- Blog: The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)
- Blog: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- Blog: Actinidia eriantha Benth. Root as a New Phytomedicine Inhibits Non-Small Cell Lung Cancer by Regulating·TGF-β/FOXO/mTOR
- Blog: Potential of Copper and Copper Compounds for Anticancer Applications
- Blog: Green synthesized gold nanoparticles from <i>Pseudobulbus Cremastrae seu Pleiones</i> show efficacy against hepatic carcinoma potentially through immunoregulation
- Blog: Design and Synthesis of Thiourea-Conjugating Organic Arsenic D-Glucose with Anticancer Activities
- Blog: Exploring the nucleotide molecular mechanism of compound kushen injection for lung adenocarcinoma based on network pharmacology and molecular docking
- Blog: Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation
- Blog: Achieving NIR Light-Mediated Tumor-Specific Fenton Reaction-Assisted Oncotherapy by Using Magnetic Nanoclusters
- Blog: Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine
- Blog: SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition
- Blog: Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies
- Blog: Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group
- Blog: Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding
- Blog: Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation
- Blog: Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
- Blog: Review of risk factors and surgical treatment progress for gallbladder cancer
- Blog: Treatment strategy for advanced or metastatic NSCLC patients with EGFR mutations after TKI-resistance: A scoping review
- Blog: Evaluating the efficacy and cardiotoxicity of EGFR-TKI AC0010 with a novel multifunctional biosensor
- Blog: PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System
- Blog: Recent Advances in Copper-Based Organic Complexes and Nanoparticles for Tumor Theranostics
- Blog: Intratumoral Injection of Engineered <i>Mycobacterium smegmatis</i> Induces Antitumor Immunity and Inhibits Tumor Growth
- Blog: A Comprehensive Analysis of <i>FGF</i>/<i>FGFR</i> Signaling Alteration in <scp>NSCLC</scp>: Implications in Prognosis and Microenvironment
- Blog: The Role of Glucose-6-Phosphate Dehydrogenase in Skin Cancer Metabolism: A Paradigm Shift in Treatment Approaches
- Blog: Magnesium in Combinatorial With Valproic Acid Suppressed the Proliferation and Migration of Human Bladder Cancer Cells
- Blog: The interaction between ncRNAs and the EGFR signaling pathway in lung cancer
- Blog: Effect of Electric Fields on the Mechanical Mechanism of Regorafenib–VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma
- Blog: <i>IPCEF1</i>: Expression Patterns, Clinical Correlates and New Target of Papillary Thyroid Carcinoma
- Blog: The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment
- Blog: Advances in Clinical Trials of Boron Neutron Capture Therapy
- Blog: 6′-Hydroxy Justicidin B Triggers a Critical Imbalance in Ca2+ Homeostasis and Mitochondrion-Dependent Cell Death in Human Leukemia K562 Cells
- Blog: AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer
- Blog: Strategies targeting angiogenesis in advanced non-small cell lung cancer
- Blog: Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients
- Blog: Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives
- Blog: Neoadjuvant chemoimmunotherapy was associated with better short‐term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy
- Blog: [Efficacy and safety of PEMD regimen in newly diagnosed early-stage non-upper respiratory digestive tract or advanced extranodal natural killer/T-cell lymphoma].
- Blog: The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3
- Blog: Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells
- Blog: [Gefitinib for non-small cell lung cancer: a meta analysis].
- Blog: Outcomes of patients treated with SVILE <i>vs</i>. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study
- Blog: Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
- Blog: Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
- Blog: Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series
- Blog: Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments
- Blog: mRNA vaccines in the context of cancer treatment: from concept to application
- Blog: Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up
- Blog: Aucubin Exerts Anticancer Activity in Breast Cancer and Regulates Intestinal Microbiota
- Blog: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
- Blog: mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
- Blog: Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer
- Blog: Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
- Blog: Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3
- Blog: Ion Interference Therapy of Tumors Based on Inorganic Nanoparticles
- Blog: Seed-derived peptide lunasin suppressed breast cancer cell growth by regulating inflammatory mediators, aromatase, and estrogen receptors
- Blog: TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations
- Blog: BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia
- Blog: Mechanism study of isoflavones as an anti-retinoblastoma progression agent
- Blog: PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
Showing 60 of 103 papers.
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_limitations_of_conventional_cancer_thera_d92b2589,
title = {limitations of conventional cancer therapies},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/limitations-of-conventional-cancer-therapies/rdr_d92b25898e554a078db6e666d6cf0feb},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 1, frozen text):
@misc{lacuna_limitations_of_conventional_cancer_thera_d92b2589_v1,
title = {limitations of conventional cancer therapies},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/limitations-of-conventional-cancer-therapies/rdr_d92b25898e554a078db6e666d6cf0feb/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}